Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant pembrolizumab with or without MK-2870 after neoadjuvant pembrolizumab plus platinum chemotherapy and surgery in resectable NSCLC without pCR
2023-508012-35-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 31
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Adjuvant MK-2870 + pembrolizumab with Adjuvant pembrolizumab alone (2 arms). Primary endpoint: Disease-free survival. Planned start Oct 2024; status: authorised.
02
Drugs
pembrolizumabsacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-508012-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508012-35-00.